Abstract
In order to reflect the risk of calcium stone formation, risk formulas have been described in the literature with the objective of being able to predict the further course of the stone disease. Some of these formulas are reviewed in this paper. Various results were obtained when different risk expressions were related to the severity of the stone disease. Although a reliable prediction of the future course of the disease most certainly cannot be made by analysis of the variables included in these expressions, several of the risk formulas differed significantly between patients with and without recurrent stone formation during a reasonable follow-up period. Some risk formulas might thus be helpful, at least to some extent, in selecting those patients in whom continuous stone formation can be anticipated and in whom active therapeutic measures should be beneficial and worthwhile. With an increased understanding of the mechanisms of calcium oxalate stone formation and our possibilities of measuring the relevant risk factors, it is likely that improved risk formulas with an increased predictive power can be developed. Until this becomes a reality, in most cases we have to combine important information on the history and clinical observations of the disease with a risk formula that offers a high degree of discrimination with respect to the risk of further stone formation.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Achilles W, Jöckel U, Schaper A, Ulshöfer B, Riedmiller H (1994) Formation of urinary stones in vitro: growth of calcium oxalate on spherulites of calcium phosphate in gel. In: Ryall R, Bais R, Marshall VR, Rofe AM, Smith LH, Walker VR (eds) Urolithiasis, vol 2 Plenum Press, New York London, pp 161–165
Ahlstrand C, Tiselius HG (1981) Metabolic effects of bendroflumethiazide in patients with recurrent calcium oxalate stone disease. J Urol 126: 635–639
Ahlstrand C, Tiselius HG, Larsson L, Hellgren E (1984) Clinical experience with long-term bendroflumethiazide treatment in calcium oxalate stone formers. Br J Urol 56: 255–262
Asplin J, Mandel NS, Coe FL (1996) Evidence for calcium phosphate supersaturation in the loop of Henle. Am J Physiol 270: F604–613
Berg C, Larsson L, Tiselius HG (1992) The effects of a single evening dose of alkaline citrate on urine composition and calcium stone formation. J Urol 148: 979–985
Brundig P, Berg W, Naumann J, Hoppe H, Cumme GA, Achilles W, Schneider HJ (1980) Kalzium-Oxalate-Aktivität-sprodukte und diskriminanzanalytische Verrechnungen von Harnparametern als grundlage eines Kalzium-Oxalat-Screening-Programmes. Urologe A 19: 54–56
Daudon M, Labrunie M, Ivaldi A, Hennequin C, Lacour B, Jungers P (1996) A new crystallization risk index (CRI) for calcium oxalate (CaOx) stone-formers. In: Pak CYC, Resnick MI, Preminger GM (eds) Urolithiasis 1996. Millet, Dallas, pp 357–358
Di Silverio F, D'Angelo AR, Gallucci M, Seccareccia F, Menotti A (1996) Incidence and prediction of stone recurrence after lithotripsy in idiopathic calcium stone patients: a multivariate approach. Eur Urol 29: 41–46
Drach GW (1976) Contribution to therapeutic decisions of ratios, absolute values and other measures of calcium, magnesium, orate or oxalate balance in stone formers. J Urol 116: 338–340
Esen T, Akinci M, Tellaloglu S (1994) Stone formation risk index (SFRI): a possible prognostic factor governing the need for metaphylaxy. In: Ryall R, Bais R, Marshall VR, Rofe AM, Smith LH, Walker VR (eds) Urolithiasis, vol 2. Plenum Press, New York London
Evans RA, Forbes MA, Sutton RAL, Watson L (1967) Urinary excretion of calcium and magnesium in patients with calcium-containing stones. Lancet II: 958–961
Fellström B, Backman U, Danielson BG, Johansson G, Ljunghall S, Wikström B (1982) Urinary excretion of orate in renal calcium stone disease and in renal tubular acidification disturbances. J Urol 127: 589–592
Gambaro G, Cicerello E, Marzaro G, Marchini F, Piccoli A, Paleari C, Baggio B (1986) A critical evaluation of the urinary inhibiting activity in idiopathic calcium oxalate nephrolithiasis. Urol Int 41: 418–421
Györy AZ, Ashby R (1996) Calcium salt urolithiasis: a radical new approach and its clinical application (abstract). J Endourol 10 [Suppl 1]: S55
Hauser W, Kunit G, Frick J (1992) Wertigkeit das Kalzium-Zitrat-Quotienten bei Kalzium-Steinbildern. Z Urol Poster 1: 36
Hess B, Kok DJ (1996) Nucleation, growth and aggregation of stone-forming crystals. In: Coe FL, Favus MJ, Pak CYC, Parks JH, Preminger GM (eds) Kidney stones. Medical and surgical management. Lippincott-Raven, Philadelphia New York, pp 3–32
Höbarth K, Hofbauer J, Szabo N (1994) Value of repeated analyses of 24-h urine in recurrent calcium urolithiasis. Urology 44: 20–25
King IS Jr, O'Connor FJ Jr, Smith MJV, Crouse L (1968) The urinary calcium/magnesium ratio in calcigerous stone formers. Invest Urol 6: 60
Kok DJ Khan SR (1995) Chances for a free or fixed particle mechanism. In: Rao PN, Kavanagh JP, Tiselius HG (eds) Urolithiais consensus and controversies. Proceeding of the Fifth European Urolithiasis Symposium, Manchester, pp 431–432
Laerum E (1984) Recurrent urolithiasis: a general-practice study of risk factors and clinical consequences. Scand J Urol Nephrol 18: 67–70
Lieske JC, Coe FL (1996) Urinary inhibitors in renal stone formation. In: Coe FL, Favus MJ, Pak CYC, Parks JH, Preminger GM (eds) Kidney stones. Medical and surgical man agement. Lippincott-Raven, Philadelphia New York, pp 65–113
Ljunghall S, Waern U (1977) Urinary electrolytes in renal stone formers and healthy subjects. A population study of 60-yearold men. Scand J Urol Nephrol Suppl 41: 55–75
Lupták J, Bek-Jensen H, Fornander AM, Höjgaard I, Nilsson MA, Tiselius HG (1994) Crystallization of calcium oxalate and calcium phosphate at supersaturation levels corresponding to those in different parts of the nephron. Scanning Microsc 8: 47–62
Marangella M, Daniele PG, Ronzani M, Sonego S, Linari F (1985) Urine saturation with calcium salts in normal subjects and idiopathic calcium stone formers estimated by an improved computer model system. Urol Res 13: 189–193
Oreopoulos DG, Soyannwo MAO, McGeown MG (1968) Magnesium/calcium ratio in urine of patients with renal stones. Lancet II: 420–422
Parks JH, Coe FL (1986) A urinary calcium-citrate index for the evaluation of nephrolithiasis. Kidney Int 30: 85–90
Robert M, Boularan AM, Delbos O, Monnier L, Grasset D (1996) Evaluation of the risk of stone formation: Study on crystalluria in patients with recurrent calcium oxalate urolithiasis. Eur Urol 29: 456–461
Robertson WG, Peacock M, Marshall RW, Marshall DH, Nordin BEC (1976) Saturation-inhibition index as a measure of the risk of calcium oxalate stone formation in the urinary tract. N Engl. J Med 294: 249–252
Robertson WG, Peacock M, Heyburn PJ, Marshall DH, Clark PB (1978) Risk factors in calcium stone disease of the urinary tract. Br J Urol 50: 449–454
Ryall RL, Marshall VR (1983) The value of the 24 h urine analysis in the assessment of stone formers attending a general hospital outpatient clinic. Br J Urol 55: 1–5
Ryall RL, Darroch JN, Marshall VR (1984) The evaluation of risk factors in male stone formers attending a general hospital out-patient clinic. Br J Urol 56: 116–121
Tiselius HG (1979) Relationship between the severity of renal stone disease and urine composition. Eur Urol 5: 322–327
Tiselius HG (1982) An improved method for the routine biochemical evaluation of patients with recurrent calcium oxalate stone disease. Clin Chim Acta 122: 409–418
Tiselius HG (1983) Different estimates of the risk of calcium oxalate crystallization in urine. Eur Urol 9: 231–234
Tiselius HG (1985) A simplified estimate of the ion-activity product of calcium phosphate in urine. Eur Urol 10: 191–195
Tiselius HG (1985) Measurement of the risk of calcium oxalate crystallization in urine. Urol Res 13: 297–300
Tiselius HG (1987) Measurement of the risk of calcium phosphate crystallization in urine. Urol Res 15: 79–81
Tiselius HG (1991) Aspects on estimation of the risk of calcium oxalate crystallization in urine. Eur Urol 47: 255–259
Tiselius HG (1994) Investigation of single and recurrent stone formers. Miner Electrolyte Metab 20: 321–327
Tiselius HG (1996) Solution chemistry of supersaturation. In: Coe FL, Favus MJ, Pak CYC, Parks JH, Preminger GM (eds) Kidney stones. Medical and surgical management. Lippincott-Raven, Philadelphia New York, pp 33–64
Tiselius HG, Larsson L (1980) Validity of biochemical findings in the evaluation of patients with urolithiasis. Eur Urol 6: 90–94
Tiselius HG, Sandvall K (1990) How are urine composition and stone disease affected by therapeutic measures at an outpatient stone clinic? Eur Urol 17: 206–212
Tiselius HG, Almgård LE, Larsson L, Sörbo B (1978) A biochemical basis for grouping of patients with urolithiasis. Eur Urol 4: 241–249
Tiselius HG, Berg C, Fornander AM, Nilsson MA (1993) Effects of citrate on the different phases of calcium oxalate crystallization. Scanning Microsc 7: 381–391
Tiselius HG, Bek-Jensen H, Fornander AM, Nilsson MA (1995) Crystallization properties in urine from calcium oxalate stone formers. J Urol 23: 215–221
Tiselius HG, Højgaard I, Fornander AM, Nilsson MA (1996) Is calcium phosphate the natural promoter of calcium oxalate crystallization? In: Pak CYC, Resnick MI, Preminger GM (eds) Urolithiasis 1996. Millet, Dallas, pp 238–239
Trinchieri A, Nespoli R, Rovera F, Currò A, Zanetti G (1996) Comparison between single renal stone formers and recurrent renal stone formers (abstract). Eur Urol 30 [Suppl 2]: 33
Wasserstein AG, Stolley PD, Soper KA, Goldfarb S, Maislin G, Agus Z (1987) Case-control study of risk factors for idiopathic calcium nephrolithiasis. Miner Electrolyte Metab 13: 85–95
Werness PG, Brown CM, Smith LH, Finlayson B (1985) Equil 2. A basic computer program for the calculation of urinary saturation. J Urol 134: 1242–1244
Yendt ER, Cohanim M (1973) 10 years experience with the use of thiazides in the prevention of kidney stones. Trans Am Clin Clim Assoc 85: 65–75
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Tiselius, HG. Risk formulas in calcium oxalate urolithiasis. World J Urol 15, 176–185 (1997). https://doi.org/10.1007/BF02201855
Issue Date:
DOI: https://doi.org/10.1007/BF02201855